Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes.
CONCLUSIONS: There were insufficient data comparing oral anti-diabetic pharmacological therapies with placebo/standard care (lifestyle advice) to inform clinical practice. There was insufficient high-quality evidence to be able to draw any meaningful conclusions as to the benefits of one oral anti-diabetic pharmacological therapy over another due to limited reporting of data for the primary and secondary outcomes in this review. Short- and long-term clinical outcomes for this review were inadequately reported or not reported. Current choice of oral anti-diabetic pharmacological therapy appears to be based on clinical preference, availability and national clinical practice guidelines.The benefits and potential harms of one oral anti-diabetic pharmacological therapy compared with another, or compared with placebo/standard care remains unclear and requires further research. Future trials should attempt to report on the core outcomes suggested in this review, in particular long-term outcomes for the woman and the infant that have been poorly reported to date, women's experiences and cost benefit.
PMID: 28120427 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Brown J, Martis R, Hughes B, Rowan J, Crowther CA Tags: Cochrane Database Syst Rev Source Type: research
More News: Acarbose | African Health | Babies | Child Development | Databases & Libraries | Depression | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Disability | Endocrinology | Fortamet | General Medicine | Insulin | International Medicine & Public Health | Metformin | Middle East Health | Neurology | Perinatology & Neonatology | Postnatal Depression | Pregnancy | Study | Women